HC Wainwright & Co. Maintains Buy on Immunogen, Raises Price Target to $27
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Immunogen (NASDAQ:IMGN) and raises the price target from $26 to $27.
August 29, 2023 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunogen's price target has been raised from $26 to $27 by HC Wainwright & Co. The firm maintains a Buy rating on the stock.
The news of a price target increase and maintained Buy rating by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100